Recida Therapeutics
Recida Therapeutics is a Biotechnology company
About Recida Therapeutics
Recida Therapeutics operates as a clinical-stage biopharmaceutical company with a dedicated focus on creating anti-infective medications to combat multi-drug resistant infections. The company was established by Frazier Healthcare Partners in 2016 and officially launched in February 2019, with co-founders including James Ge, Vernon Jiang, George H. Talbot, and Paul Eckburg. The leadership team brings to the table significant experience in the development of antibiotics, including well-known drugs like doripenem, ceftaroline, and ceftolozane/tazobactam.
The company's business model is centered on the clinical development and subsequent commercialization of novel antibiotics. A key part of its strategy involves forming partnerships to advance its product pipeline. For instance, Recida has licensed the development and commercialization rights for its lead candidate, RC-01, from FUJIFILM Toyama Chemical Co. for all territories outside of Japan. Additionally, a partnership with MicuRx Pharmaceuticals, Inc. covers the development and commercialization of RC-01 in the greater China region. Funding for Recida's operations has been secured through a Series A financing round of $8.5 million led by Frazier Healthcare Partners and a grant of up to $4.4 million from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research and development.
Recida's primary product candidate is RC-01, a novel LpxC inhibitor designed to treat multidrug-resistant Gram-negative infections. The drug functions by inhibiting LpxC, a crucial enzyme for the survival of Gram-negative bacteria. This mechanism represents a new class of antibiotics, a significant development considering no new class of anti-gram-negative antibiotics has been successfully developed in over 65 years. RC-01 has demonstrated potent activity against a wide range of clinically relevant pathogens, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. A notable feature is its activity against highly resistant P. aeruginosa isolates from cystic fibrosis patients. In April 2019, Recida initiated a Phase I clinical trial in the United States to evaluate the safety, tolerability, and pharmacokinetics of RC-01. Preclinical studies showed a favorable safety profile, avoiding toxicities seen in previous LpxC inhibitors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Menlo Park, United States
- Open positions
- None listed
- Dealroom signal
- 45.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2019 | $8.5M | $34M | Frazier Healthcare Partners | — |
| CONVERTIBLE✓Equity / VC | Jul 2018 | $5.7M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Recida Therapeutics is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Recida Therapeutics in the Menlo Park ecosystem
The Recida Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Frazier Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Recida Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Recida Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









